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Rhesus macaques were immunized with a replication-deficient vaccinia virus (MVA) expressing human immunodeficiency
virus type 1 89.6 envelope (env) and SIV gagpol (MVA/SHIV89.6) with or without a protein boost consisting of soluble 89.6
env (gp140). Immunization with MVA/SHIV89.6 alone elicited binding antibodies in all animals and neutralizing antibodies in
5 of 15 animals. Both types of antibodies were enhanced by protein boosting. In addition, CD8 cells exhibiting CM9 tetramer
binding were detected in the subset of animals that were Mamu-A*01 positive. Animals were challenged intravenously with
either SHIV-89.6 (Study 1) or the more pathogenic derivative SHIV-89.6P (Study 2). In Study 1, all control and vaccinated
animals except one became infected. However, the levels of viremia were as follows: controls  rMVA alone  rMVA 
protein. The differences were statistically significant between immunized and control groups but not between the two
immunized groups. In Study 2, all animals became infected; however, the vaccinated group exhibited a 5-fold reduction in
peak viremia and a 10-fold reduction in the postacute phase viremia in comparison to the controls. All of the controls required
euthanasia by 10 months after challenge. A relationship between vaccine-induced antibody titers and reduction in virus
burden was observed in both studies. Thus, immunization with MVA/SHIV89.6 alone or with a protein boost stimulated both
arms of the immune system and resulted in significant control of viremia and delayed progression to disease after challenge
with SHIV-89.6P. © 2002 Elsevier Science (USA)INTRODUCTION
Development of a safe and effective vaccine against
human immunodeficiency virus type 1 (HIV-1) is the focus
of worldwide efforts. Numerous vaccine modalities have
been tested in animal models, including soluble recom-
binant proteins (Earl et al., 2001; Heeney et al., 1999;
Kumar et al., 2000; Stott et al., 1998; VanCott, 1997;
Verschoor et al., 1999), DNA vectors (Barouch et al., 2000;
Boyer et al., 1996, 1997; Cherpelis et al., 2001; Egan et al.,
2000; Lu et al., 1996a; Mossman et al., 1999; Shiver et al.,
1997; Wang et al., 2000), recombinant viruses (Barouch et
al., 2001; Buge et al., 1997; Caley et al., 1997; Ourmanov
et al., 2000; Robert-Guroff et al., 1998; Seth et al., 1998),
and various prime–boost combinations (Amara et al.,
2001; Cho et al., 2001; Hirsch et al., 1996; Kent et al., 1998;
Letvin et al., 1997; Polacino et al., 1999; Robinson et al.,
1999). In general, DNA and recombinant virus vectors
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270stimulate cellular immunity (Amara et al., 2001; Barouch
et al., 2000; Robinson, 1997; Seth et al., 1998) while
subunit proteins are more effective at inducing antibod-
ies (Barnett et al., 1997; Berman et al., 1990; Clements-
Mann et al., 1998; Earl et al., 2001; Graham et al., 1993).
An ideal vaccine would stimulate both arms of the im-
mune system.
Poxviruses are attractive vaccine vectors because of
their large capacity for added DNA and ability to induce
cellular and humoral immune responses in both animal
models and humans. Although vaccinia virus was exten-
sively used to prevent smallpox, safety concerns have
led to the testing of avian poxviruses and highly attenu-
ated strains of vaccinia virus as vaccine vectors. Modi-
fied vaccinia virus Ankara (MVA) was attenuated for use
as a safe smallpox vaccine by serial passage in chicken
embryo fibroblasts (CEF). During these passages, the
virus underwent numerous deletions and other muta-
tions resulting in an inability to efficiently replicate in
most mammalian cells, though it still replicates to high
titer in CEF (Antoine et al., 1998; Carroll and Moss, 1997;Key Words: SHIV89.6; SHIV-89.6P; vaccine; recombinant
protein.
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Mayr et al., 1975; Meyer et al., 1992). Consequently, MVA
was safe when administered to humans and was aviru-modifie
on
lent even for immunosuppressed animals (Mahnel and
Mayr, 1994; Mayr et al., 1975, 1978; Stittelaar et al., 2001).
Because the replication defect in human cells affected
virus assembly, viral and recombinant gene expression
remained unimpaired (Sutter and Moss, 1992). Most im-
portantly, recombinant MVA induced protective cellular
and humoral immune responses in both small animals
and nonhuman primates that were at least as good as
those achieved by standard replicating strains of vac-
cinia virus (Belyakov et al., 1998; Hirsch et al., 1996;
Sutter et al., 1994). The immunogenicity of MVA may have
been enhanced by the spontaneous deletion of many
immune evasion genes during the extensive passage
history of MVA (Antoine et al., 1998; Blanchard et al.,
1998).
The inability of HIV to cause disease in nonhuman
primates has led to the development of the simian–
human hybrid virus or SHIV (Lu et al., 1996b). SHIV-89.6
was created by replacing the envelope (env), tat, and rev
genes of SIV with those from the dual-tropic clade B
primary isolate 89.6 (Reimann et al., 1996b). It replicates
at high levels for several weeks in macaques but then
declines in magnitude without causing serious disease.
A more pathogenic derivative, termed SHIV-89.6P, was
isolated after serial passage of SHIV-89.6 in macaques
(Reimann et al., 1996a). SHIV-89.6P exhibits more robust
and prolonged replication resulting in rapid CD4 T cell
loss and subsequent AIDS-like disease and death. The
difference between the two viruses has been attributed
to 12 amino acid changes in gp120, which affect not only
the replicative potential and pathogenic capacity of the
virus but also the neutralization characteristics (Crawford
et al., 1999; Karlsson et al., 1997). Thus, sera from mon-
keys infected with SHIV-89.6 do not readily neutralize
SHIV-89.6P.
For the studies described here, we immunized rhesus
macaques with MVA/SHIV89.6, a recombinant MVA
(rMVA) that expresses the env, gag, and polymerase (pol)
genes of SHIV-89.6. Some groups of animals were
boosted with soluble oligomeric 89.6 Env. Animals were
challenged intravenously with SHIV-89.6 or SHIV-89.6P.
Both vaccine protocols resulted in reduced replication of
the challenge virus.
RESULTS
Construction and characterization of MVA/SHIV89.6
We constructed a rMVA, named MVA/SHIV89.6, that
produces Env, Gag, and Pol proteins. This virus contains
a truncated 89.6 env (gp160T) gene and the gagpol gene
from SIVmac239 in MVA deletions II and III, respectively.
Both are regulated by the mH5 promoter which yields
enhanced early expression, a factor that has been
shown to be important for generation of CTL in mice
(Coupar et al., 1986). Further enhancement of early env
gene expression was achieved by genetic alteration of
the naturally occurring T5NT sequences within the 89.6
env gene without changing the amino acid sequence
(Earl et al., 1990).
Protein expression, induced by rMVA encoding env or
gagpol or both, was analyzed by immunoprecipitation as
shown in Fig. 1A. The gp160T precursor was produced
and cleaved into gp41T and gp120, some of which was
shed into the medium (not shown). The biological func-
tion of the expressed dual-tropic Env was demonstrated
by fusion of MVA/SHIV89.6-infected cells with cells ex-
pressing CD4 and either CCR5 or CXCR4 (L. Wyatt,
manuscript in preparation). Gag precursors p55 and p41
FIG. 1. Protein expression and VLP production by cells infected with
MVA/SHIV89.6. (A) HIV and SIV antigens were immunoprecipitated from
cells infected with single recombinant viruses (MVA/89.6T or MVA/
SIV239gagpol) or double recombinant virus (MVA/SHIV89.6) using rab-
bit HIV-1 env serum and serum from an SIV-infected monkey. Both
precursor and cleaved proteins are shown: HIV-89.6 gp160(T), gp120,
and gp41(T) and SIV p55gag, p27, and p17. (B) Cells were infected with
either MVA/SHIV89.6 or MVA/SIV239gagpol, fixed, embedded in plastic,
and stained with uranyl acetate. Note the appearance of spikes around
the edges of particles formed by infection with MVA/SHIV89.6.
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as well as cleavage products p27 and p17 were also
produced (Fig. 1A). Virus-like particles (VLP), recovered
by sedimentation of the medium of infected cells through
a sucrose cushion, contained Gag products p27 and p17,
as well as reverse transcriptase activity (not shown).
To visualize VLP, thin sections of infected cells were
analyzed by electron microscopy. Budding and released
VLP were seen with both the double recombinant, MVA/
SHIV89.6, and the single recombinant, MVA/
SIV239gagpol (Fig. 1B). The surface of VLP formed from
the double recombinant had a characteristic fuzzy ap-
pearance not seen in those formed from the single re-
combinant, suggestive of the presence of Env spikes. In
support of this, Env was visualized on VLP produced by
MVA/SHIV89.6 by immunogold labeling with Env-specific
antibodies while no labeling was found in VLP produced
by MVA/SIV239gagpol (not shown).
Vaccine-induced humoral responses in rhesus
macaques
Studies were designed to test the immunogenicity of
SHIV-89.6 proteins expressed by MVA/SHIV89.6 alone or
after boosting with soluble oligomeric gp140. After two
immunizations with MVA/SHIV89.6, all of the animals
developed antibody to 89.6 Env as measured by enzyme-
FIG. 2. Temporal antibody responses—Study 1. (A) Serum IgG end-point titers were measured by ELISA using 89.6 gp140 captured via antibody
to the C-terminus of gp120. (B) SHIV-89.6 neutralizing antibody titers were determined in an MT-2 cell killing assay. Titers are the reciprocal of the
dilution giving 50% neutralization. Thin and thick arrows depict times of MVA/SHIV89.6 and soluble 89.6 gp140 immunizations, respectively. The time
of challenge with SHIV-89.6 is shown by the dotted vertical line.
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linked immunosorbent assay (ELISA) (Figs. 2A and 3A).
Titers were enhanced after both the third and fourth
MVA/SHIV89.6 immunizations with geometric mean titers
of 2.1  104 and 6.8  104, respectively. Protein boosting
increased ELISA titers (geometric mean) to 3.1  105
and 4.7  105 in Studies 1 and 2, respectively (Figs. 2A
and 3A).
Neutralizing antibodies to SHIV-89.6 developed after
three or four immunizations with MVA/SHIV89.6 (Figs. 2B
and 3B). After three immunizations, 3 of the 15 animals
had reciprocal titers between 51 and 102. The fourth
MVA/SHIV89.6 immunization (Study 1) boosted the titers
in 3 of the 5 animals, with reciprocal titers ranging from
33 to 139. Boosting with gp140 enhanced the neutralizing
titers in 4 of 5 animals in Study 1 and 3 of 5 animals in
Study 2, with reciprocal titers ranging from 49 to 1195. In
addition, 4 of the 10 animals that received the protein
boost developed neutralizing antibody against the heter-
ologous SHIV-89.6P (1:14 to 1:37) (see Table 1).
Vaccine-induced CTL responses in rhesus macaques
CTL responses for the SIV Gag epitope CM9 bound by
Mamu-A*01 (Altman et al., 1996) were assessed in the
five Mamu-A*01-positive vaccines at week 60 or 62 of the
study, at which time the monkeys had received either
four immunizations with MVA/SHIV89.6 or three immuni-
zations with MVA/SHIV89.6 and two protein boosts. Tet-
ramer binding was detected in fresh peripheral blood
mononuclear cells (PBMC) from four of the five animals,
ranging from 0.14 to 0.54% of the CD3CD8 cells (Table
1). After in vitro stimulation, cells from all animals stained
with Mamu-A*01/CM9 tetramer and exhibited specific
lysis in a functional chromium release assay (Table 1).
Virus loads after challenge with nonpathogenic
SHIV-89.6 (Study 1)
The 13 animals (10 vaccinated with MVA/SHIV89.6 and
3 with control MVA) in Study 1 were challenged intrave-
nously with 10 animal infectious doses of SHIV-89.6 4
weeks after the fourth MVA/SHIV89.6 immunization or 2
weeks after the second protein boost. The final boosting
was staggered to allow all animals to be challenged on
the same day. Plasma viral RNA loads were determined
by a quantitative NASBA assay (Fig. 4). Viral RNA was
undetectable in animal 605 at all times after challenge.
The total viral RNA load (geometric mean) in the control
FIG. 3. Temporal antibody responses—Study 2. (A) Serum IgG end-point titers were measured by ELISA using 89.6 gp140 captured via antibody
to the C-terminus of gp120. (B) SHIV-89.6 neutralizing antibody titers were determined in an MT-2 cell killing assay. Titers are the reciprocal of the
dilution giving 50% neutralization. Thin and thick arrows depict times of MVA/SHIV89.6 and soluble 89.6 gp140 immunizations, respectively. The time
of challenge with SHIV-89.6P is shown by the dotted vertical line. Open and closed symbols represent animals that are alive or dead 17 months after
challenge, respectively.
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group of animals was 1 log higher than that in either
vaccinated group (P  0.0335 and 0.0125 using the
Fisher test; P  0.05 and 0.016 using Shaeffer’s modifi-
cation of the Bonferonni method). Although the RNA
levels of the protein boost group were lower than the
rMVA alone group, the difference was not considered
statistically significant.
The infection status of the animals was determined
with two additional assays. First, PBMC from the mon-
keys were cocultured with CEM cells and p27 was quan-
tified from the supernatant. Cells from all animals except
605 were positive for at least one time point after chal-
lenge (data not shown). Second, seroconversion to p27
was assayed by ELISA. All animals except 605 strongly
seroconverted to p27 in this assay (data not shown).
Humoral responses following challenge
with SHIV-89.6
ELISA binding titers to Env increased after challenge
in all control and all vaccinated animals except 605 (Fig.
2A). Geometric mean titers increased from 6.7  104
(MVA/SHIV89.6) and 3.1  105 (MVA/SHIV89.6  gp140)
prior to challenge to 1.4  106 (both groups) by 6 weeks
postchallenge, suggesting a secondary response in-
duced by replication of SHIV-89.6 in vaccinated animals.
At this time the challenged control animals had a geo-
metric mean titer of only 3.3  105.
Neutralizing antibody responses to SHIV-89.6 were
observed in all control animals by 12 weeks postchal-
lenge (1:35–1:110). In 3 of the 10 immunized animals
(Nos. 615, 617, and 623), a spike in titer (up to 1:619–1:
1031) was seen within 4 to 8 weeks after challenge.
Animal 605, which had the second highest prechallenge
neutralizing antibody titer (1:171), showed a drop in both
binding and neutralizing antibodies postchallenge, con-
sistent with its apparent resistance to infection as mea-
sured by plasma RNA and virus isolation. SHIV-89.6
infection typically results in development and mainte-
nance of high neutralizing antibody titers. In the MVA/
SHIV89.6  gp140 group, neutralizing antibody titers
TABLE 1
Summary
Immunogen
Animal
no.
Peak neutralizing antibody
titer (reciprocal dilution)a
Mamu-A*01/CM9
tetramer % CD8
T cellsa
51Cr release E:T (25:1)
% specific lysisa
Challenge
virus
Peak RNA
(copies/ml)SHIV-89.6 SHIV-89.6P
Fresh
PBMC
Stimulated
PBMC
MVA 599 20 5 SHIV-89.6 5.6 106
600 20 5 1.4 106
601 20 5 1.6 106
Average: 2.9 106
MVA/SHIV-89.6 615 139 19 SHIV-89.6 5.0 104
616b 47 5 0.20 26 37.9 5.1 105
617 23 5 1.2 105
622b 20 5 0.15 22 28.3 5.0 104
623 33 9 6.7 105
Average: 2.8 105
MVA/SHIV-89.6
 gp140
605b 171 25 0.09 10 66.0 SHIV-89.6 5.0 103
606 20 5 1.2 106
607b 261 26 0.14 17 61.5 1.2 105
608 112 37 0.03 0.18 1.7 5.0 104
609 52 5 8.5 104
Average: 2.9 105
MVA 602 20 5 SHIV-89.6P 1.1 108
603 20 5 1.9 108
604 20 5 4.5 107
Average: 1.2 108
MVA/SHIV-89.6
 gp140
610 210 5 SHIV-89.6P 2.9 107
611b 34 5 0.54 68 67.7 1.6 107
612 49 5 1.4 108
613 1195 14 4.8 105
614 20 5 3.1 107
Average: 4.3 107
a Prechallenge values.
b Mamu-A*01 positive.
274 EARL ET AL.
were low to undetectable for several months (see Fig.
2B, weeks 71–91) following challenge in 3 of the 4 in-
fected animals, suggesting that the animals were able to
temporarily control viral replication.
Virus loads after challenge with SHIV-89.6P
Approximately 1 year after the third immunization with
MVA/SHIV89.6 one unchallenged group of animals was
boosted with Env protein (Study 2). Following intravenous
challenge with 10 animal infectious doses of the patho-
genic SHIV-89.6P, all of the animals became infected
(Fig. 5A). In the three control animals, viral RNA peaked
at 2 weeks postchallenge with a geometric mean of
9.7  107 copies/ml. RNA was then maintained at levels
of 105 to 106 copies/ml. In the five vaccinated animals,
viral RNA loads varied considerably. At the peak, the
geometric mean was 1.7  107 RNA copies/ml, fivefold
lower than in the controls (Fig. 5A). However, RNA values
quickly dropped to low levels in two animals and de-
clined more slowly in two others. The profile from animal
FIG. 4. Temporal viral RNA loads after challenge with SHIV-89.6—Study 1. Plasma viral RNA (copies/ml) was determined by NASBA. Data from
individual animals are plotted. The statistical significance of comparison between each vaccinated group and control group is given.
FIG. 5. Temporal viral RNA loads, CD4 cell counts, and neutralizing antibody titers against SHIV-89.6P—Study 2. (A) Plasma viral RNA (copies/ml)
was determined by NASBA. Plot lines terminate at the time of death; three animals (Nos. 610, 611, and 613) are still alive. (B) CD4 T cell counts were
measured by FACS. (C) SHIV-89.6P neutralizing antibody titers were determined in an MT-2 cell killing assay. Titers are the reciprocal of the dilution
giving 50% neutralization. Data from individual animals are plotted. Open and closed symbols represent animals that are alive or dead 20 months after
challenge, respectively.
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612, however, was similar to that of the controls. A sta-
tistically significant difference between the log RNA val-
ues in the control and vaccinated groups was reached in
the postacute phase of infection (P  0.032).
Humoral responses following challenge
with SHIV-89.6P
After challenge with SHIV-89.6P, Env ELISA titers in-
creased rapidly in all five vaccinated monkeys (Fig. 3A)
as expected, since the 89.6 and 89.6P Env proteins are
very similar. The geometric mean titers increased from
4.7  105 on the day of challenge to 6.6  106 4 weeks
later, suggestive of an anamnestic response that had
been primed by vaccination. By comparison, titers to 89.6
Env were at least two orders of magnitude lower in the
control animals. In addition, enhanced neutralization of
SHIV-89.6 (Fig. 3B) and SHIV-89.6P (Fig. 5C) was seen in
all vaccinated animals following the challenge. The chal-
lenged control animals developed only low levels of
binding antibodies and no neutralizing antibodies
against either the vaccine or the challenge virus (Fig.
5C). Thus, immunization with MVA/SHIV89.6 primed for a
secondary neutralizing antibody response to SHIV-89.6
as well as SHIV-89.6P.
CD4 T cell counts and clinical outcome in animals
challenged with SHIV-89.6P
All control monkeys exhibited a rapid and dramatic
loss of CD4 T cells within 3 weeks after challenge (Fig.
5B). A similar pattern was seen in one vaccinated mon-
key (No. 612). Two others (Nos. 611 and 614) also had
severe loss of CD4 cells but the decline occurred more
slowly than in the controls, reaching similar levels only at
week 21 after challenge. Animals 610 and 613 have
maintained CD4 cell levels at 500 cells/l for 20
months.
The animals were followed for clinical signs of dis-
ease after challenge. To date, all three control and two
vaccinated animals (Nos. 612 and 614) have been eutha-
nized due to severe AIDS-like symptoms including
chronic diarrhea, weight loss, poor appetite, and unre-
sponsiveness to therapy. The remaining three vaccinated
monkeys remain in good health with no evident signs of
disease. We found, as have others, that high RNA levels
and CD4 cell decline were associated with more rapid
disease progression and death.
DISCUSSION
Induction of both humoral and cellular immunity are
goals in development of an effective HIV vaccine. To this
end we designed a preclinical immunization protocol
aimed at stimulating both arms of the immune system.
We chose the SHIV model that incorporates the env gene
from the primary HIV-1 isolate 89.6 and constructed a
rMVA virus, MVA/SHIV89.6, that expresses functional
89.6 env and SIVmac239 gagpol. While production of
correctly folded and functional proteins is not necessary
for eliciting CTL, it is likely to be important for generation
of potent neutralizing antibodies. As a means of enhanc-
ing antibody production, we included a protein boost,
consisting of oligomeric 89.6 gp140, in some of the study
groups.
Our studies were designed to answer several ques-
tions. First, could we generate both humoral and cellular
immunity with the rMVA alone? Second, does boosting
with soluble Env enhance immunogenicity? Third, can
either immunization protocol effectively lower viral loads
after challenge with a homologous SHIV? And finally,
using the pathogenic SHIV challenge, does immuniza-
tion limit not only virus replication but also virus-induced
CD4 T cell loss and progression to AIDS-like disease?
Immunization with MVA/SHIV89.6 elicited both binding
and neutralizing antibodies, with the former appearing
earlier and more consistently in all animals. In contrast,
Barouch et al. (2001) found no evidence of neutralizing
antibodies after three successive immunizations of ma-
caques with a mixture of the two single rMVA viruses that
were used to generate our MVA/SHIV89.6. Perhaps un-
der those conditions most cells were not simultaneously
infected with the two viruses so that small amounts of
VLP containing Env were formed. In addition, Amara et
al. (2001) did not detect neutralizing antibodies after two
DNA immunizations followed by a single boost with
MVA/SHIV89.6. We found substantially enhanced anti-
body titers after a protein boost. However, they were not
as high as those obtained in animals immunized 4–6
times with 89.6 Env alone (P. Earl, unpublished results).
In addition, neutralization of SHIV-89.6P was found in 4 of
the 10 animals that received protein boosting. Thus,
although enhancement of the humoral response was
achieved by administration of soluble Env, a more effec-
tive immunogen is needed to further increase both the
magnitude and the breadth of the antibody response.
We also detected a CTL response to Gag in Mamu-
A*01-positive animals by CM9 tetramer staining of
PBMC. Peak tetramer staining was previously reported
to occur at 1–2 weeks following a second or third rMVA
immunization (Barouch et al., 2001; Seth et al., 1998,
2000). Other groups have reported a correlation between
peak tetramer staining and reduction in virus load (Ba-
rouch et al., 2000, 2001). Since our study was initiated
before the tetramer technology was widely available, we
performed the assay at only a single time point, just prior
to challenge, when the T cell pools were in memory
phase. Because of this as well as the limitation in num-
ber of Mamu-A*01 animals in the study, no correlations
with virus load were possible.
In Study 1, following intravenous challenge with SHIV-
89.6, all but one vaccinated animal and all control ani-
mals became infected. Nevertheless, both groups of im-
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munized animals exhibited a statistically significant re-
duction in viral load in comparison to the control group.
The viral RNA loads were lower in the protein boost
group than in the group that received only recombinant
MVA. Interestingly, the animal that apparently resisted
infection (No. 605) was one that received the protein
boost and had one of the highest vaccine-induced neu-
tralizing antibody titers, but the lowest tetramer staining.
Using data from both groups of immunized animals and
excluding controls, we found an inverse correlation be-
tween peak prechallenge neutralizing antibody titer and
log total viral RNA. Although the P value (0.089, deter-
mined by either Kendall or Spearman rank correlation)
did not reach statistical significance, it is suggestive that
neutralizing antibodies contributed to the control of vire-
mia. In another study, we found that repeated immuniza-
tion of monkeys with 89.6 Env alone induced neutralizing
antibodies in all animals. In addition, those animals with
the highest titers (1:2000 at peak) were fully protected
against SHIV-89.6 challenge, indicating that with suffi-
ciently high neutralizing antibodies, protection can be
achieved in the absence of CTL (P. Earl, unpublished
results). Our observations that antibody production is
enhanced after boosting with protein and that there is a
relationship between higher neutralizing antibody titers
and lower viral burden have implications for upcoming
efficacy trials in which inclusion of a protein boost fol-
lowing canarypox immunization is under consideration.
The consequences of infection with SHIV-89.6P differ
dramatically from those of SHIV-89.6 in that replication is
persistent, CD4 cells undergo dramatic depletion, and
animals develop AIDS-like disease in most cases
(Reimann et al., 1996a). In addition, the neutralizing spec-
ificities of the 89.6 Env in the vaccine and the 89.6P Env
in the challenge virus differ. This challenge virus thus
offers the opportunity to evaluate protection from immu-
nologic suppression and disease in circumstances in
which there is some Env heterogeneity. Although all of
the animals became infected following intravenous chal-
lenge with SHIV-89.6P, the control animals exhibited uni-
formly high viral RNA loads, dramatic loss of CD4 cells,
and onset of AIDS-like disease typical of infection with
SHIV-89.6P. Although there was wide variation in the
responses of the immunized animals, as a group they
exhibited a considerable reduction in plasma viremia,
CD4 cell loss, and progression to disease. With the
exception of animal 612, which behaved like the unim-
munized controls, the kinetics of CD4 loss were much
slower in the immunized group. Currently, 20 months
following challenge, three of the five immunized mon-
keys (Nos. 610, 611, and 613) are alive and healthy.
Prechallenge neutralizing antibodies to SHIV-89.6
were detected in four of the five immunized animals in
Study 2 (Table 1). Animals 613 and 610, which had the
highest neutralizing titers against SHIV-89.6 (1:1195 and
1:200, respectively), exhibited the lowest viral RNA loads
and the most consistent preservation of CD4 T cells,
supporting the role of neutralizing antibodies in control of
infection. Although the only Mamu-A*01 animal in this
group had a relatively high percentage of tetramer-pos-
itive CD8 T cells, it showed a progressive loss of CD4
cells.
Further evidence for the protective effects of immuni-
zation came from the postchallenge neutralizing anti-
body titers. Secondary responses to SHIV-89.6 were ob-
served within 2–4 weeks of challenge in all of the immu-
nized animals in Study 2. In addition, these animals
developed neutralizing antibodies to the challenge
strain, SHIV-89.6P, within 4 to 6 weeks of challenge.
These latter antibodies could reflect either an anamnes-
tic response by a small subset of B cells that were
primed by vaccination or a de novo response to the
challenge virus that was made possible due to CD4 cell
preservation. In contrast, none of the control animals
seroconverted to either SHIV strain because of the rapid
loss of immune function.
In summary, our studies showed that immunization
with rMVA induces both antibodies and CTL, although
the former were enhanced by addition of a protein boost.
Significant reduction of viremia was achieved against
either a completely or partially homologous challenge
strain. With the pathogenic virus, this translated into CD4
cell preservation and prolonged survival. In addition, our
data suggested that neutralizing antibodies played a role
in controlling viremia, although cell-mediated immunity
could also have made a significant contribution to pro-
tection.
MATERIALS AND METHODS
Construction of rMVAs
A recombinant virus expressing the SIVmac239 gagpol
gene was constructed by insertion of the entire open
reading frame from plasmid p239SpSp5 into a plasmid
transfer vector, pLW-9 (Wyatt et al., 1996). The rMVA,
MVA/SIV239gagpol, was selected by immunostaining
with serum from an SIV-infected macaque. For construc-
tion of the double recombinant virus, CEF were incu-
bated simultaneously with 5 infectious units each of
MVA/SIV239gagpol and MVA/89.6T (L. Wyatt, manuscript
in preparation). Cells infected with MVA/SIV239gagpol
have a unique rounded-up appearance unlike that seen
with nonrecombinant MVA or env-expressing recombi-
nant MVA. Thus, we picked foci composed of rounded
cells that stained positively for Env. Approximately 20% of
the foci had this characteristic. The double recombinant
virus was clonally purified and amplified.
Immunoprecipitation of viral antigens
from MVA-infected cells
Infection, metabolic labeling, and immunoprecipitation
were performed as previously described (Sugiura et al.,
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1999). Briefly, BS-C-1 cells were infected with 5 to 10
infectious units/cell. Five hours postinfection, cell mono-
layers were washed once and overlaid with methionine-
free EMEM containing 5% dialyzed FBS and 100 Ci of
[35S]methionine (New England Nuclear, Boston, MA) per
milliliter. After 20 h, cells were lysed in buffer containing
100 mM Tris–HCl, pH 8.0, 100 mM NaCl, and 0.5% Triton
X-100. Cell lysates were clarified by centrifugation for 10
min at top speed in a microfuge and subjected to immu-
noprecipitation with rabbit HIV-Env serum 2144 and mon-
key serum p211. Proteins were separated by 10% poly-
acrylamide SDS electrophoresis and visualized by auto-
radiography.
Electron microscopy of VLP
BS-C-1 cells were infected at a multiplicity of infection
of 10. After 24 h, the cells were prepared for conventional
transmission electron microscopy as previously de-
scribed (da Fonseca et al., 2000).
Immunization and challenge of rhesus macaques
A total of 21 rhesus monkeys (Macaca mulatta) were
used in two studies (13 in Study 1 and 8 in Study 2).
Experiments were conducted in an AAALAC-Interna-
tional accredited facility and in accordance with guide-
lines set forth in the National Research Council Guide for
the Care and Use of Laboratory Animals (1996). The
studies were conducted under Contract N01-AI65314 by
the Division of AIDS, NIAID, NIH. Vaccinated (n  5) and
control (n  3) groups were immunized intramuscularly
with 108 infectious units of either MVA/SHIV89.6 or non-
recombinant MVA at 0, 4, and 26 weeks. Study 1 con-
sisted of two experimental groups: one received an ad-
ditional MVA/SHIV89.6 immunization at week 60,
whereas the other received two immunizations with 300
g of soluble, oligomeric 89.6 gp140 at weeks 40 and 62.
The 89.6 gp140 was produced from BS-C-1 cells infected
with recombinant vaccinia virus vBD1 and purified by
lentil lectin and Superdex 200 chromatography (P. Earl,
unpublished results). The 89.6 gp140 boosts were ad-
ministered in QS-21 adjuvant (Aquila Biopharmaceuti-
cals, Inc., Framingham, MA). Study 2 consisted of one
experimental group that received three immunizations
with MVA/SHIV89.6 followed by boosting with 89.6 gp140
at weeks 85 and 98. Monkeys in Study 1 were chal-
lenged intravenously with 10 animal infectious doses of
the nonpathogenic SHIV-89.6 (obtained from Yichen Lu,
Virus Research Institute, Cambridge, MA) 4 weeks after
the fourth MVA immunization or 2 weeks after the second
protein immunization. The final immunizations were stag-
gered to allow simultaneous challenge of all monkeys.
Monkeys in Study 2 were challenged intravenously with
10 animal infectious doses of the pathogenic SHIV-89.6P
(obtained from Norman Letvin, Beth Israel Deaconess
Medical Center, Harvard Medical School, Boston, MA) 2
weeks after the second protein boost.
89.6 Env ELISA
For the ELISA, Immulon-2 (Dynex Technologies, Chan-
tilly, VA) 96-well U-bottomed plates were coated over-
night at 4°C with sheep antibody to the C-terminus of
gp120 (International Enzymes, Inc., Fallbrook, CA) at 0.5
g/ml in bicarbonate buffer (Roche Molecular Biochemi-
cals, Indianapolis, IN). Purified 89.6 gp140 was captured
(0.6 g/ml in PBS) for 2 h at room temperature. Plates
were blocked with 5% nonfat dry milk in PBS. Then
twofold serial dilutions of monkey sera were incubated
for 2 h at room temperature followed by horseradish
peroxidase-conjugated anti-monkey IgG (Accurate Chemi-
cal and Scientific Corp, Westbury, NY) for 1 h and
then BM Blue substrate (Roche Molecular Biochemi-
cals) for 30 min. Absorbency was measured at 370 and
492 nm.
Neutralization of SHIV-89.6 and SHIV-89.6P
Neutralization was measured in an MT-2 cell assay as
described previously (Crawford et al., 1999; Montefiori et
al., 1988). Virus stocks were produced in human PBMC.
Titers of neutralizing antibodies were presented as the
reciprocal of the serum dilution that reduced virus-in-
duced cell killing by 50% as measured by neutral red dye
uptake.
CTL assays
51Cr release assays were performed on in vitro stimu-
lated PBMC (Allen et al., 2000).
MHC typing
Rhesus macaques were typed for the rhesus MHC
class I molecule Mamu-A*01 by PCR sequence-specific
priming and direct sequencing as previously described
(Knapp et al., 1997).
Tetramer staining
A total of 1 106 fresh, unstimulated PBMC or 2 105
lymphocytes from 2-week peptide-stimulated cultures
were washed three times in FACS buffer (PBS from Gibco
with 2% FCS from BioCell) in a 96-well U-bottom plate.
Cells (100 l) were incubated for 40 min at room tem-
perature in the dark with Mamu-A*01/CM9-tetramer la-
beled with either phycoerythrin or allophycocyanin (0.5
g/100 l for fresh PBMC, 0.1 g/100 l for in vitro
cultures) together with 10 l anti-rhesus fluorescein iso-
thiocyanate-labeled CD3 monoclonal antibody (Bio-
Source, San Jose, CA) and 6 l anti-CD8-PerCP mono-
clonal antibody (clone SK1, Becton Dickinson) in a 100-l
volume of FACS buffer. The Mamu-A*01 molecule was
refolded with the GagCM9 peptide and the tetramers
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were made as described previously (Allen et al., 1998;
Altman et al., 1996). Plates were then washed four times
with FACS buffer. Finally, 450 l of 2% paraformaldehyde
in PBS was added to fix the stained cells. A CTL clone
specific for these tetramers was stained in parallel with
isotype controls (mouse IgG1-FITC, Biosource; mouse
IgG2a-PE, Immunotech; mouse IgG1-PerCP, BD; mouse
IgG1-APC, Immunotech), anti-CD3-FITC, anti-CD8-PE
(Immunotech), anti-CD8-PerCP, or CD8-APC (Immuno-
tech) to establish compensation parameters. Samples
were stored in the dark at 4°C and acquisition of
100,000–200,000 lymphocyte-gated events was per-
formed on a Becton Dickinson FACSCalibur instrument
and analyzed using CellQuest software (Becton Dickin-
son Immunocytometry Systems, San Jose, CA). Back-
ground tetramer staining of fresh, unstimulated PBMC
from naive Mamu-A*01-positive animals was routinely
less than 0.09% and less than 0.2 for in vitro stimulated
cultures (data not shown).
Plasma SHIV RNA copy number
The concentration of SHIV RNA in plasma was deter-
mined by quantitative nucleic acid sequence-based am-
plification (NASBA) assays (Romano et al., 2000).
CD4 T cell counts
Flow cytometric assays were performed on PBMC by
FAST Systems, Inc. (Gaithersburg, MD).
Statistical methods
Analysis of variance (ANOVA) was used to test for
differences in RNA loads between study groups using
log-transformed data. Calculations were performed with
StatView (SAS Institute, Inc., Cary, N.C.). In addition, we
applied Shaffer’s improved method for multiple, pairwise
comparisons among a set of tests (Shaffer, 1986). This
procedure, an extension of earlier work by Holm (1979),
is a sequentially rejective method that can significantly
improve on the Bonferroni method, while still protecting
the family-wise error rate.
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